1. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12(2):
78e89. https://doi:10.1177/1479164114561992.
2. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in
diabetes mellitus. Annu Rev Med. 2015;66(1):255e270. https://doi:10.1146/
annurev-med-051013-110046.
3. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects
of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26e39.
https://doi:10.1016/j.kint.2017.12.027.
4. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2
inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Publ Health. 2019;16(16):2965. https://doi:10.3390/ijerph16162965.
5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes,
and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117e2128.
https://doi:10.1056/NEJMoa1504720.
6. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and
renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644e657. https://
doi:10.1056/NEJMoa1611925.
7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of
kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323e334. https://
doi:10.1056/NEJMoa1515920.
8. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes
in type 2 diabetes: results from the CANVAS program randomised clinical trials.
Lancet Diabetes Endocrinol. 2018;6(9):691e704. https://doi:10.1016/S22138587(18)30141-4.
9. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes
in type 2 diabetes. N Engl J Med. 2019;380(4):347e357. https://doi:10.1056/
NEJMoa1812389.
10. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of
kidney failure in patients with type 2 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol. 2019;7(11):845e854. https://doi:10.1016/
S2213-8587(19)30256-6.
346
H. Yaginuma, R. Banno, R. Sun et al.
Journal of Pharmacological Sciences 147 (2021) 340e347
27. Neumann UH, Denroche HC, Mojibian M, Covey SD, Kieffer TJ. Insulin knockout
mice have extended survival but volatile blood glucose levels on leptin therapy. Endocrinology. 2016;157(3):1007e1012. https://doi:10.1210/en.20151890.
28. Togashi Y, Shirakawa J, Okuyama T, et al. Evaluation of the appropriateness of
using glucometers for measuring the blood glucose levels in mice. Sci Rep.
2016;6(1):25465. https://doi:10.1038/srep25465.
29. Ito Y, Banno R, Shibata M, et al. GABA type B receptor signaling in proopiomelanocortin neurons protects against obesity, insulin resistance, and hypothalamic inflammation in male mice on a high-fat diet. J Neurosci. 2013;33(43):
17166e17173. https://doi:10.1523/JNEUROSCI.0897-13.2013.
30. Fujikawa T, Chuang J-C, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in
mice. Proc Natl Acad Sci Unit States Am. 2010;107(40):17391e17396. https://
doi:10.1073/pnas.1008025107.
31. Perry RJ, Petersen KF, Shulman GI. Pleotropic effects of leptin to reverse insulin
resistance and diabetic ketoacidosis. Diabetologia. 2016;59(5):933e937.
https://doi:10.1007/s00125-016-3909-4.
32. Heyman E, Berthon P, Youssef H, et al. Metabolic dysfunction in late-puberty
adolescent girls with type 1 diabetes: relationship to physical activity and dietary intakes. Diabetes Metab. 2012;38(4):337e342. https://doi:10.1016/j.
diabet.2012.03.001.
33. Denroche HC, Kwon MM, Glavas MM, et al. The role of autonomic efferents and
uncoupling protein 1 in the glucose-lowering effect of leptin therapy. Mol
Metab. 2016;5(8):716e724. https://doi:10.1016/j.molmet.2016.06.009.
34. Chiba Y, Yamada T, Tsukita S, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals
in mice. PloS One. 2016;11(3):150756. https://doi:10.1371/journal.pone.
0150756.
35. Hsu WC, Okeke E, Cheung S, et al. A cross-sectional characterization of insulin
resistance by phenotype and insulin clamp in East Asian Americans with type 1
and type 2 diabetes. PloS One. 2011;6(12):28311. https://doi:10.1371/journal.
pone.0028311.
36. Huml M, Kobr J, Siala K, et al. Gut peptide hormones and pediatric type 1
diabetes mellitus. Physiol Res. 2011;60(4):647e658. https://doi:10.33549/
physiolres.931995.
37. Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin
promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice.
EBioMedicine. 2017;20:137e149. https://doi:10.1016/J.EBIOM.2017.05.028.
38. Xu P, Ye X, Zhang Y, et al. Long-acting hypoglycemic effects of PEGylated FGF21
and insulin glargine in mice with type 1 diabetes. J Diabet Complicat.
2015;29(1):5e12. https://doi:10.1016/J.JDIACOMP.2014.10.001.
39. Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract.
2016;22(2):220e230. RA https://doi:10.4158/EP15869.
40. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment
in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care.
2015;38(6):971e978. https://doi:10.2337/dc15-0078.
11. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type
2 diabetes, 2018. A consensus report by the American diabetes association
(ADA) and the European association for the study of diabetes (EASD). Diabetes
Care. 2018;41(12):2669e2701. https://doi:10.2337/dci18-0033.
12. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter
2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm
Pharmacol. 2014;66(7):975e987. https://doi:10.1111/jphp.12223.
13. Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic control
with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial
dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med.
2016;3:43. https://doi:10.3389/fcvm.2016.00043.
14. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in
patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week
study. Diabetes Care. 2018;41(12):2552e2559. https://doi:10.2337/dc18-1087.
15. Araki E, Watada H, Uchigata Y, et al. Efficacy and safety of dapagliflozin in
Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52week results from a randomized, open-label, phase III clinical trial. Diabetes
Obes Metabol. 2020;22(4):540e548. https://doi:10.1111/dom.13922.
16. Paik J, Blair HA. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019;79(17):
1877e1884. https://doi:10.1007/s40265-019-01213-x.
17. McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes.
Diabetologia. 2018;61(10):2126e2133. https://doi:10.1007/s00125-018-46716.
18. Miyanaga F, Ogawa Y, Ebihara K, et al. Leptin as an adjunct of insulin therapy in
insulin-deficient diabetes. Diabetologia. 2003;46:1329e1337. https://doi:10.
1007/s00125-003-1193-6.
19. Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia. 2016;59(5):928e932. https://doi:10.1007/s00125-016-3898-3.
20. Xu J, Bartolome CL, Low CS, et al. Genetic identification of leptin neural circuits
in energy and glucose homeostases. Nature. 2018;556(7702):505e509. https://
doi:10.1038/s41586-018-0049-7.
21. Fujikawa T, Berglund ED, Patel VR, et al. Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin. Cell Metabol.
2013;18(3):431e444. https://doi:10.1016/j.cmet.2013.08.004.
22. Denroche HC, Levi J, Wideman RD, et al. Leptin therapy reverses hyperglycemia
in mice with streptozotocin-induced diabetes, independent of hepatic leptin
signaling. Diabetes. 2011;60(5):1414e1423. https://doi:10.2337/db10-0958.
23. Perry RJ, Peng L, Abulizi A, Kennedy L, Cline GW, Shulman GI. Mechanism for
leptin's acute insulin-independent effect to reverse diabetic ketoacidosis. J Clin
Invest. 2017;127(2):657e669. https://doi:10.1172/JCI88477.
24. Vasandani C, Clark GO, Adams-Huet B, Quittner C, Garg A. Efficacy and safety of
metreleptin therapy in patients with type 1 diabetes: a pilot study. Diabetes
Care. 2017;40(5):694e697. https://doi:10.2337/dc16-1553.
25. Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective
inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic
mice. J Pharmacol Sci. 2012;120(1):36e44. https://doi:10.1254/jphs.12089FP.
26. Denroche HC, Kwon MM, Quong WL, et al. Leptin induces fasting hypoglycaemia in a mouse model of diabetes through the depletion of glycerol.
Diabetologia. 2015;58(5):1100e1108. https://doi:10.1007/s00125-015-3529-4.
347
...